Navigation Links
Spherix Announces Termination of Arla License Agreement
Date:6/23/2009

Agreement Enables Spherix to Pursue All Pharmaceutical and Health-Oriented Nutraceutical Uses of Naturlose

BETHESDA, Md., June 23 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has terminated the 1996 license agreement pursuant to which it granted Arla Foods Ingredients Amba ("Arla") the food and beverage rights to D-tagatose. Per the termination agreement, Spherix and Arla have fully released one another from all obligations.

"While we recognize the potential value that D-tagatose has as a food and beverage additive, we are currently focusing on the potentially more profitable uses of tagatose (brand name "Naturlose(R)") as a novel pharmaceutical treatment for Type 2 diabetes. Spherix is very satisfied with the progress of the clinical trials for Naturlose, currently in Phase 3, and recently announced full-scale cGMP manufacturing of the compound. Leaving open the option to use D-tagatose in both foods or beverages, and as a pharmaceutical compound, provides Spherix with greater flexibility and long-term upside," said Dr. Claire Kruger, CEO of Spherix. Nutraceutical or functional foods (foods with health-promoting or dietary management properties beyond the basic function of supplying nutrients) are a growing segment of the industry due to their increasing popularity with health-conscious consumers.

Spherix is currently investigating Naturlose as a treatment for Type 2 diabetes in a Phase 3 clinical trial. The company expects preliminary results from this Phase 3 study in the fall of 2009, and plans to file a New Drug Application (NDA) with the FDA shortly after the conclusion of the Phase 3 st
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
2. Spherix Regains Full NASDAQ Compliance
3. Spherix to Exhibit at the BIO 2009 International Convention
4. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
5. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
6. Spherix Announces 2008 Financial Results
7. Spherix Reports 3rd Quarter Earnings
8. Spherix Transfers Stock Listing to Nasdaq Capital Market
9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
10. Spherix Receives NASDAQ Bid Price Deficiency Letter
11. Spherix Reports 1st Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2008 R&D 100 Awards Now Online, ROCKAWAY, N.J., ... the 8th Annual Innovator of the Year and 43rd ... exemplify the,ideals of R&D in academia, industry, and nationally ... with ten finalists,-- five scientists and five innovators -- ...
... TOLEDO is pleased to announce that Dr. Francis Stoessel, ... Institute (SWISSI), will be the Keynote Speaker in the ... , ... Columbia, MD ...
... ALBANY, Ore., Sept. 30 Synthetech, Inc. (OTC,Bulletin ... Frederic,Farkas as Director of Manufacturing effective on October ... consulting services to Synthetech. Dr. Farkas,has over 13 ... API,manufacturing from previous positions in manufacturing and supply ...
Cached Biology Technology:2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced 2Synthetech Announces New Director of Manufacturing 2
(Date:4/15/2014)... in nanoparticle form could help reduce side effects by ... years, scientists have developed nanoparticles that deliver one or ... to design particles that can carry any more than ... have devised a new way to build such nanoparticles, ... different drugs. In a paper published in the ...
(Date:4/15/2014)... University of Adelaide research into parasites of cuttlefish, ... parasites, astonishing life cycles, and shown how they ... , Researcher Dr Sarah Catalano has described 10 ... in the kidneys of cephalopods (cuttlefish, squid and ... species to be described from Australian waters. ...
(Date:4/14/2014)... hard pill to swallow, but if you,re over 24 ... terms of your cognitive motor performance, according to a ... Thompson, a psychology doctoral student, associate professor Mark Blair, ... actuarial science doctoral student, deliver the news in a ... In one of the first social science experiments to ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Bizarre parasite may provide cuttlefish clues 2Study says we're over the hill at 24 2
... first detailed molecular images of a piece of the spike-shaped ... and initiate the first stages of infection. The structure, which ... scientists learn new details about how the virus infects cells. ... points that can be exploited by novel antiviral drugs or ...
... the Albert Einstein College of Medicine have discovered a ... may soon be able to resist the effects of ... disease-causing microbes, including Shigella and E. coli, are rapidly ... was led by Dr. John S. Blanchard, the Dan ...
... genetics of barley could lead to improved varieties of ... whisky and beer. Scientists funded in part by the ... a new programme to uncover key genes that control ... research, being carried out at the Scottish Crop Research ...
Cached Biology News:Learning how SARS spikes its quarry 2Learning how SARS spikes its quarry 3Einstein researchers identify new way that bacteria develop resistance to antibiotics 2Whisky fans can drink to crop research 2
... Combining linear motor and ballscrew ... pre-engineered Cartesian solutions that include ... management, and motors., , ... Pass through high-flex cabling for ...
UGT1A6 (D-20)...
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
... designed for moving loads quickly and accurately. ... output while limiting overall size. The P5S-P ... ball bearings guided on two rails., ... provide energy absorption and controlled deceleration , ...
Biology Products: